secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0000950170-25-094789
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences effects 1-for-3 reverse stock split; PRIME Phase 1b enrollment expected to complete July 2025
--------------------------------------------------------------------------------

- 1-for-3 reverse stock split effective July 7, 2025; post-split shares ~1,534,599.
- Split intended to regain Nasdaq minimum bid price compliance; CUSIP changed to 76135L705.
- PRIME Phase 1b study of Gemini in CKD patients: enrollment expected to complete July 2025; topline data anticipated shortly after.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025094789/0000950170-25-094789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025094789/revb-20250707.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-094789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer